Abstract：
Therapeutic hypothermia is now standard of care for neonates with hypoxic-ischemic encephalopathy (HIE) in high income countries (HIC). Conversely, compelling trial evidence suggests that hypothermia is ineffective, and may be deleterious, in low- and middle-income countries (LMIC), likely reflecting the lower proportion of infants who had sentinel events at birth, suggesting that injury had advanced to a stage when hypothermia is no longer effective. Although hypothermia significantly reduced the risk of death and disability in HICs, many infants survived with disability and in principle may benefit from targeted add-on neuroprotective or neurorestorative therapies. The present review will assess biomarkers that could be used to personalize treatment for babies with HIE - to determine first whether an individual infant is likely to respond to hypothermia, and second, whether additional treatments may be beneficial.
摘要：
在高收入国家（HIC），治疗性低温已成为治疗新生儿缺氧缺血性脑病（HIE）的标准。相反，令人信服的试验证据表明低温是无效的,可能是有害的，在低收入和中等收入国家(LMIC)，可能反映了出生时发生前哨事件的婴儿比例较低，这表明损伤已经发展到低温不再有效的阶段。虽然低温显著降低了HIC的死亡和残疾风险，许多婴儿残疾存活下来,原则上可从有针对性的附加神经保护或神经修复治疗中获益.本综述将评估可用于HIE婴儿个性化治疗的生物标志物-首先确定单个婴儿是否可能对体温过低做出反应，第二,是否额外的治疗可能是有益的。
